These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25457851)

  • 1. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa.
    Fiorino G; Danese S
    Gastroenterology; 2014 Dec; 147(6):1433-5. PubMed ID: 25457851
    [No Abstract]   [Full Text] [Related]  

  • 2. Etrolizumab in moderate-to-severe ulcerative colitis.
    Armuzzi A; Felice C
    Lancet; 2014 Jul; 384(9940):285-6. PubMed ID: 24814088
    [No Abstract]   [Full Text] [Related]  

  • 3. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etrolizumab for ulcerative colitis: the new kid on the block?
    Makker J; Hommes DW
    Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P; Hart A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
    [No Abstract]   [Full Text] [Related]  

  • 6. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
    Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Agrawal M; Verstockt B
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):2-4. PubMed ID: 34798035
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.
    Wei X; Kenny JR; Dickmann L; Maciuca R; Looney C; Tang MT
    J Clin Pharmacol; 2016 Jun; 56(6):693-704. PubMed ID: 26412221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for the treatment of ulcerative colitis.
    Rietdijk ST; D'Haens GR
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of interleukin 13 blockade in ulcerative colitis.
    Tilg H; Kaser A
    Gut; 2015 Jun; 64(6):857-8. PubMed ID: 25804632
    [No Abstract]   [Full Text] [Related]  

  • 13. Visilizumab in severe ulcerative colitis: good vision but blurry results.
    Sparrow M
    Inflamm Bowel Dis; 2008 Jul; 14(7):1022-3. PubMed ID: 18383522
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. Authors' reply.
    Bokemeyer B; Plachta-Danielzik S
    Aliment Pharmacol Ther; 2024 Jan; 59(1):142-143. PubMed ID: 37924219
    [No Abstract]   [Full Text] [Related]  

  • 15. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
    Actis GC; Lagget M; Pellicano R; Rosina F
    Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
    [No Abstract]   [Full Text] [Related]  

  • 16. Does it all ADA up? Adalimumab for ulcerative colitis.
    Travis S
    Gut; 2011 Jun; 60(6):741-2. PubMed ID: 21257988
    [No Abstract]   [Full Text] [Related]  

  • 17. Etrolizumab: anti-β7-a novel therapy for ulcerative colitis.
    Lin KK; Mahadevan U
    Gastroenterology; 2014 Jan; 146(1):307-9. PubMed ID: 24269566
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccinating patients with inflammatory bowel disease--primum non nocere.
    Muhammad R; Wong CL; Limdi JK
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1122-3. PubMed ID: 22554229
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Warner B; Harris AW
    Gastroenterology; 2012 Jul; 143(1):e42; author reply e42. PubMed ID: 22634354
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of leukocyte trafficking in inflammatory bowel disease.
    Cominelli F
    N Engl J Med; 2013 Aug; 369(8):775-6. PubMed ID: 23964940
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.